



North Carolina
State Health Plan
FOR TEACHERS AND STATE EMPLOYEES



Pharmacy & Therapeutics Committee December 2016 Meeting Summary

Board of Trustees Meeting

January 27, 2017

A Division of the Department of State Treasurer

2017 Pharmacy Formulary Evaluation

- **The Plan's Pharmacy and Therapeutics (P&T) Committee met on December 13, 2016, to conduct a final review on the closed formulary and the exception process.**
 - **Formulary Exception Process:**
 - Reviewed exception criteria questions and process for provider requests
 - **Non-formulary Medication Review:**
 - Medications slated for non-formulary status under new closed formulary reviewed by therapeutic class, engaging P&T members by specialty
 - Committee voted to approve the non-formulary medications as presented, with the exception of five medications where clinical concerns were expressed

Drugs for Formulary Customization Consideration

Drug	Class/Indication
Farydak (panobinostat)	Oncology multiple myeloma, refractory
Tasigna (nilotinib)	Oncology leukemia, chronic myelogenous
Alecensa (alectinib)	Oncology Non-small cell lung cancer, ALK positive
Cabometyx (cabozantinib)	Oncology Renal cell carcinoma, advanced Thyroid cancer, medullary
Belsomra (suvoraxant)	Neurology Insomnia

Next Steps

- **Clinical Information:**

- Gathering Pharmacy Benefit Manager's clinical rationale and financial impact of potential customization requests

- Note: the P&T committee agreed that the final decision for exclusion or inclusion in the formulary would be made by the Plan's Executive Administrator. In the interim, providers will be guided to the formulary exception process.